Two-Drug immunotherapy combo shows promise for advanced kidney cancer
NCT ID NCT02964078
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tested a combination of two immunotherapy drugs—high-dose interleukin-2 (IL-2) and pembrolizumab (Keytruda)—in 27 adults with metastatic kidney cancer. The goal was to see if the combination could shrink or eliminate tumors. Participants received both drugs in a coordinated schedule, and the main outcome measured was the overall response rate (how many patients had their tumors shrink or disappear).
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Could an ALS drug clear the fog of chemo brain?
- Ancient Mind-Body practice tested as fatigue fighter for men after cancer
- Can a website help cancer survivors live healthier? large study tests online lifestyle coaching
- Drug that starves tumors shows promise against advanced kidney cancer
- Could a common bile acid pill shield kidneys during cancer surgery?